Therapeutic efficacy and safety of ciprofloxacin and co-trimoxazole combination versus ciprofloxacin in urinary tract infection in Sudan
Abstract
In Sudan there is no sufficient data about treatment of urinary tract infection and the emerging resistance for ciprofloxacin 500mg BD and the adoption of maximum dose of ciprofloxacin 750mg BD to overcome the resistance. That exposed the patients for more adverse effects. The alternative prescription of the second and third generation cephalosporin are very expensive and there is emerging resistance of cephalosporin by Enterobacteriace bacteria secreted β-lactmase (Sibhghatulla Shaikh,Jamale Fatima&ShaziShakilet al, 2015).Therefore, this study was set out to evaluate the efficacy and safety of ciprofloxacin 500mg and TMP-SMX 80/400mg (80 mg trimethoprim and 400 mg sulfamethxazole) versus ciprofloxacin 750mg BD in the management of urinary tract infection . It was prospective, experimental, randomized, parallel-group clinical study, conducted at Elmek Nimer University Hospital, in Shendi. Sudan between August 2019 and August 2020. A total of three hundred (300) patients diagnosed with urinary tract infection were enrolled in this study. They were classified into control group included one hundred and fifty (150 ) patients received oral ciprofloxacin 750mg BID for four (4) days for patients with uncomplicated UTI and 7 days for patients with complicated UTI . The test group included one hundred and fifty (150 ) patients received oral combination of ciprofloxacin 500mg and cotrimoxazole (TMP-SMX 80/400mg) BD for the same duration of treatment. The effectiveness endpoint and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 34 participants or records.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.